Company profile
Home | Akamis Bio | Tumor Gene Therapy
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
PSC08 | Transaction MzQ0NDA5NTg4M2FkaXF6a2N4
Published 19 Nov 2024 10:58
SH01 | Transaction MzQ0MzM0NTYyMWFkaXF6a2N4
Published 14 Nov 2024 09:14
AA | Transaction MzQ0MjU2MTA0N2FkaXF6a2N4 | Paper/PDF filed
Published 14 Nov 2024 09:11
RP04SH01 | Transaction MzQ0MTg2NDc1MWFkaXF6a2N4
Published 06 Nov 2024 11:40
PSC09 | Transaction MzQ0MTg2ODMzM2FkaXF6a2N4
Published 04 Nov 2024 10:21
AP01 | Transaction MzQ0MTkwMTY5MWFkaXF6a2N4
Published 04 Nov 2024 02:19
RESOLUTIONS | Transaction WUREWVo0Mk9hZGlxemtjeA | Paper/PDF filed
Published 28 Oct 2024 06:39
MA | Transaction MzQ0MDA1NDg4NWFkaXF6a2N4 | Paper/PDF filed
Published 28 Oct 2024 06:39
SH01 | Transaction MzQ0MDY2MzQyNGFkaXF6a2N4 | Paper/PDF filed
Published 07 Nov 2024 07:07
SH10 | Transaction MzQ0MDA4ODYzOWFkaXF6a2N4 | Paper/PDF filed
Published 23 Oct 2024 06:33
SH08 | Transaction MzQ0MDA4ODU1MWFkaXF6a2N4 | Paper/PDF filed
Published 23 Oct 2024 06:23
TM01 | Transaction MzQ0MDA1ODc3NGFkaXF6a2N4
Published 18 Oct 2024 10:35
TM01 | Transaction MzQ0MDA1ODc4MWFkaXF6a2N4
Published 18 Oct 2024 10:35
TM01 | Transaction MzQ0MDA1ODc4NGFkaXF6a2N4
Published 18 Oct 2024 10:35
TM01 | Transaction MzQ0MDA1ODc4NmFkaXF6a2N4
Published 18 Oct 2024 10:35
TM01 | Transaction MzQ0MDA1ODc3OGFkaXF6a2N4
Published 18 Oct 2024 10:35
TM01 | Transaction MzQ0MDA1ODc3MmFkaXF6a2N4
Published 18 Oct 2024 10:35
AP01 | Transaction MzQ0MDA1NzExMmFkaXF6a2N4
Published 18 Oct 2024 10:23
AP01 | Transaction MzQ0MDA1NzAzMWFkaXF6a2N4
Published 18 Oct 2024 10:22
Company registered at Companies House
1 Feb 2013 to 31 Dec 2016
ColoAd1 is a chimeric adenovirus serotype 3/11p, with a number of key characteristics that may make it a suitable oncolytic agent for the potential treatment of metastatic carcinomas. This is a phase I/IIa study designed to determine the safety, toxicity and tolerability of ColoAd1 and the clinical benefit and potential efficacy of ColoAd1 as a single age...
